Glido M2 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 2mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral glucose uptake and utilization, contributing to improved insulin sensitivity. The synergistic action of these agents effectively lowers blood glucose levels, aiding in the maintenance of glycemic targets. Glido M2 Tablet PR is typically prescribed when diet, exercise, and monotherapy with either agent are insufficient to achieve adequate glycemic control. It is essential to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and patient tolerance. Caution is advised in patients with renal or hepatic impairment, cardiovascular disease, or a history of lactic acidosis. Common adverse effects include gastrointestinal disturbances, hypoglycemia, and weight gain. Patient education on adherence, lifestyle modification, and recognition of hypoglycemia symptoms is crucial for optimal outcomes. Glido M2 Tablet PR should be used under medical supervision with periodic assessment of renal function and glycemic status.